A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults
Condition: Respiratory Disorders Interventions: Biological: Blood sampling; Biological: Formulation 1 : NTHi-Mcat high dose adjuvanted vaccine GSK3277513A; Biological: Formulation 2 : NTHi-Mcat low dose adjuvanted vaccine GSK3339036A; Drug: Placebo Sponsor: GlaxoSmithKline Not yet recruiting - verified June 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 19, 2017 Category: Research Source Type: clinical trials
A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults
Condition: Respiratory Disorders Interventions: Biological: Blood sampling; Biological: Formulation 1 : NTHi-Mcat high dose adjuvanted vaccine GSK3277513A; Biological: Formulation 2 : NTHi-Mcat low dose adjuvanted vaccine GSK3339036A; Drug: Placebo Sponsor: GlaxoSmithKline Not yet recruiting - verified July 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 19, 2017 Category: Research Source Type: clinical trials
A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults
Condition: Respiratory Disorders Interventions: Biological: Blood sampling; Biological: Formulation 1 : NTHi-Mcat high dose adjuvanted vaccine GSK3277513A; Biological: Formulation 2 : NTHi-Mcat low dose adjuvanted vaccine GSK3339036A; Drug: Placebo Sponsor: GlaxoSmithKline Not yet recruiting - verified June 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 19, 2017 Category: Research Source Type: clinical trials